

Perspectives Of Specialists On Anti-amyloid Monoclonal Antibodies Therapy For Early Alzheimer's Disease In Thailand

Saowarin Padermprach,MD, Chatchawan Rattanabannakit,MD,Vorapun Senanarong, FRCP(London)
Division of Neurology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University
Address: Faculty of Medicine Siriraj Hospital, 2, Wanglang, Bangkoknoi, Bangkok, 10700, Thailand E-mail: saowarin.pad@mahidol.ac.th



Mahidol University
Faculty of Medicine Siriraj Hospital

BACKGROUND

The approval of anti-amyloid monoclonal antibodies (mAbs) is a major breakthrough for early-stage Alzheimer's disease, but implementing these high-cost, high complexity therapies in resource-limited, middle-income countries like Thailand presents significant infrastructure challenges.

OBJECTIVES

To evaluate perspectives, clinical confidence, and perceived barriers regarding anti-amyloid monoclonal antibody (mAbs) therapy among Thai dementia care specialists including neurologists, psychiatrists and geriatricians.

METHODS

1. DESIGN & PARTICIPANTS

Web-based NATIONAL cross-sectional survey.
Thai neurologists, psychiatrists, and geriatricians.

2. SURVEY CONTENT

Specialist demographics.
Clinical knowledge of anti-amyloid mAbs.
Perspectives on implementation and barriers.

3. TOOLS

Electronic questionnaire covering key areas.
5-point Likert scales used for perspectives assessment.


4. ANALYSIS

DESCRIPTIVE STATISTICS applied.
Key metrics: frequency, mean, and standard deviation (SD).

RESULTS



RESULTS



CONCLUSION

While Thai specialists recognize the therapeutic potential of anti-amyloid monoclonal antibodies (mAbs), substantial concerns regarding financial burden, clinical confidence, and safety monitoring persist. Successful implementation may be supported by standardized clinical guidance for administration and safety monitoring, alongside consideration of context-appropriate strategies to address treatment affordability and accessibility in Thailand.

REFERENCES

• van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer's disease. N Engl J Med. 2023;388(1):9–21.
• Sims JR, Zimmer JA, Evans CD, et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023;330(6):512–527.
• Dementia Association of Thailand. Dementia Association of Thailand Statement on the Use of Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer's Disease [Internet]. Bangkok: Dementia Association of Thailand; 2025 Oct 03.